所有图片(1)

文件

安全信息

安全和法规

PHR1526

地塞米松

Name: 地塞米松
Brand: SIAL

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

地塞米松, (11β,16α)-9-氟-11,17,21-三羟基-16-甲基孕甾-1,4-二烯-3,20-二酮, 9α-氟-16α-甲基-11β,17α,21-三羟基-1,4-妊娠双烯-3,20-二酮, 9α-氟-16α-甲基泼尼松龙, 泼尼松龙F

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₂H₂₉FO₅

CAS号:

50-02-2

分子量:

392.46

Beilstein:

2066651

EC 号:

200-003-9

MDL编号:

MFCD00064136

UNSPSC代码:

41116107

PubChem化学物质编号:

329823438

NACRES:

NA.24

生物来源

synthetic

质量水平

300

等级

certified reference material
pharmaceutical secondary standard

Agency

BP
EP
USP
traceable to BP 578
traceable to Ph. Eur. D0700000
traceable to USP 1176007

蒸汽压

<0.0000001 kPa ( 25 °C)

API类

dexamethasone

CofA

current certificate can be downloaded

包装

pkg of 1 g

储存条件

protect from light

技术

HPLC: suitable
gas chromatography (GC): suitable

颜色

white

mp

262-264 °C (lit.)

溶解性

DMSO: soluble
acetone: sparingly soluble
chloroform: slightly soluble
dioxane: soluble
ethanol: sparingly soluble
ether: very slightly soluble
methanol: sparingly soluble
water: practically insoluble

应用

pharmaceutical (small molecule)

格式

neat

运输

ambient

储存温度

2-30°C

SMILES字符串

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

InChI key

UREBDLICKHMUKA-CXSFZGCWSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问产品对比指南

一般描述

Dexamethasone is a corticosteroid medication, with anti-inflammatory activity. It is widely used for inflammatory ocular conditions and for the treatment of skin-allergic reactions.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

应用

Dexamethasone may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using voltammentric techniques and reversed-phase high-performance liquid chromatography technique.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

生化/生理作用

糖皮质激素抗炎剂。调节T细胞生存、生长和分化。抑制一氧化氮合酶活性的诱导。

分析说明

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

其他说明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

附注

To see an example of a Certificate of Analysis for this material enter LRAC2894 in the slot below. This is an example certificate only and may not be the lot that you receive.

警示用语：

Danger

危险声明

H360FD

预防措施声明

P201 - P202 - P280 - P308 + P313 - P405 - P501

危险分类

Repr. 1B

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Simultaneous determination of dexamethasone and moxifloxacin in pharmaceutical formulations using stability indicating HPLC method

Razzaq NS, et al.

Arabian Journal of Chemistry, 10(3), 321-328 (2017)

Determination of prednisolone, dexamethasone and hydrocortisone in pharmaceutical formulations and biological fluid samples by voltammetric techniques using b-cyclodextrin modified carbon paste electrode

Balaji K, et al.

African Journal of Pharmacy and Pharmacology, 2(8), 157-166 (2008)

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.

Sara Bringhen et al.

Blood, 124(1), 63-69 (2014-05-24)

This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who

Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production.

Michael J White et al.

Cell, 159(7), 1549-1562 (2014-12-20)

Activated caspases are a hallmark of apoptosis induced by the intrinsic pathway, but they are dispensable for cell death and the apoptotic clearance of cells in vivo. This has led to the suggestion that caspases are activated not just to kill

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Lotfi Benboubker et al.

The New England journal of medicine, 371(10), 906-917 (2014-09-04)

The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. We randomly

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件

安全信息

地塞米松

Pharmaceutical Secondary Standard; Certified Reference Material

About This Item

属性

生物来源

质量水平

等级

Agency

蒸汽压

API类

CofA

包装

储存条件

技术

颜色

mp

溶解性

应用

格式

运输

储存温度

SMILES字符串

InChI

InChI key

基因信息

相关类别

说明

一般描述

应用

生化/生理作用

分析说明

其他说明

附注

推荐产品

相关产品

相关产品

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

WGK

闪点(°F)

闪点(°C)

法规信息

文件

分析证书(COA)

已有该产品？

同行评审论文

技术服务